Huadong Medicine Co., Ltd (SHE:000963)
China · Delayed Price · Currency is CNY 36.28
+0.39 (1.09%)
Feb 3, 2026, 3:04 PM CST
Huadong Medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 42,695 | 41,508 | 40,261 | 37,489 | 34,418 | 33,604 |
Other Revenue | 397.3 | 397.3 | 362.43 | 226 | 145.56 | 78.83 |
| 43,092 | 41,906 | 40,624 | 37,715 | 34,563 | 33,683 | |
Revenue Growth (YoY) | 3.32% | 3.16% | 7.71% | 9.12% | 2.61% | -4.97% |
Cost of Revenue | 28,490 | 28,006 | 27,468 | 25,686 | 23,969 | 22,555 |
Gross Profit | 14,602 | 13,899 | 13,156 | 12,028 | 10,595 | 11,128 |
Selling, General & Admin | 7,781 | 7,806 | 8,066 | 7,584 | 6,591 | 6,969 |
Research & Development | 1,985 | 1,426 | 1,271 | 1,016 | 979.64 | 926.73 |
Other Operating Expenses | 215.34 | 214.72 | 203.41 | 205.31 | 176.11 | 184.37 |
Operating Expenses | 10,120 | 9,558 | 9,566 | 8,873 | 7,788 | 8,103 |
Operating Income | 4,482 | 4,341 | 3,590 | 3,155 | 2,806 | 3,025 |
Interest Expense | -96.91 | -96.95 | -114.91 | -120.04 | -68.48 | -68.64 |
Interest & Investment Income | 96.31 | 104 | 94.05 | 103.35 | 80.4 | 60.99 |
Currency Exchange Gain (Loss) | -2.56 | -2.56 | -1.04 | -34.7 | -2.27 | -10.04 |
Other Non Operating Income (Expenses) | 0.67 | -27.16 | -29.65 | -27.16 | -31.93 | -16.68 |
EBT Excluding Unusual Items | 4,480 | 4,318 | 3,538 | 3,076 | 2,784 | 2,990 |
Impairment of Goodwill | - | - | - | - | -2.92 | - |
Gain (Loss) on Sale of Investments | -161.85 | -129.19 | -233.47 | -113.09 | -96.31 | -27.53 |
Gain (Loss) on Sale of Assets | -5.82 | -5.46 | 4.32 | 8.26 | -0.03 | 322.64 |
Asset Writedown | -25.19 | -25.19 | -5.14 | -5.87 | -5.09 | -2.51 |
Other Unusual Items | 143.19 | 143.19 | 161.87 | 65.6 | 147.89 | 170.41 |
Pretax Income | 4,430 | 4,302 | 3,466 | 3,031 | 2,828 | 3,453 |
Income Tax Expense | 756.81 | 807.33 | 619.59 | 498.5 | 488.91 | 543.67 |
Earnings From Continuing Operations | 3,673 | 3,494 | 2,846 | 2,533 | 2,339 | 2,910 |
Minority Interest in Earnings | 24.25 | 17.92 | -7.54 | -33.41 | -37 | -89.86 |
Net Income | 3,698 | 3,512 | 2,839 | 2,499 | 2,302 | 2,820 |
Net Income to Common | 3,698 | 3,512 | 2,839 | 2,499 | 2,302 | 2,820 |
Net Income Growth | 15.12% | 23.71% | 13.59% | 8.58% | -18.38% | 0.24% |
Shares Outstanding (Basic) | 1,754 | 1,752 | 1,750 | 1,750 | 1,750 | 1,750 |
Shares Outstanding (Diluted) | 1,756 | 1,753 | 1,752 | 1,750 | 1,750 | 1,750 |
Shares Change (YoY) | 0.26% | 0.08% | 0.10% | 0.00% | -0.00% | 0.00% |
EPS (Basic) | 2.11 | 2.00 | 1.62 | 1.43 | 1.32 | 1.61 |
EPS (Diluted) | 2.11 | 2.00 | 1.62 | 1.43 | 1.32 | 1.61 |
EPS Growth | 14.82% | 23.61% | 13.47% | 8.58% | -18.37% | 0.24% |
Free Cash Flow | 1,971 | 2,021 | 2,323 | 1,189 | 2,351 | 1,938 |
Free Cash Flow Per Share | 1.12 | 1.15 | 1.33 | 0.68 | 1.34 | 1.11 |
Dividend Per Share | 0.930 | 0.930 | 0.580 | 0.290 | 0.290 | 0.230 |
Dividend Growth | - | 60.35% | 100.00% | - | 26.09% | -17.86% |
Gross Margin | 33.88% | 33.17% | 32.38% | 31.89% | 30.65% | 33.04% |
Operating Margin | 10.40% | 10.36% | 8.84% | 8.37% | 8.12% | 8.98% |
Profit Margin | 8.58% | 8.38% | 6.99% | 6.63% | 6.66% | 8.37% |
Free Cash Flow Margin | 4.57% | 4.82% | 5.72% | 3.15% | 6.80% | 5.75% |
EBITDA | 5,249 | 5,091 | 4,318 | 3,778 | 3,316 | 3,456 |
EBITDA Margin | 12.18% | 12.15% | 10.63% | 10.02% | 9.59% | 10.26% |
D&A For EBITDA | 767.02 | 750.15 | 727.64 | 622.73 | 509.65 | 431 |
EBIT | 4,482 | 4,341 | 3,590 | 3,155 | 2,806 | 3,025 |
EBIT Margin | 10.40% | 10.36% | 8.84% | 8.37% | 8.12% | 8.98% |
Effective Tax Rate | 17.08% | 18.77% | 17.88% | 16.45% | 17.29% | 15.74% |
Revenue as Reported | 43,092 | 41,906 | 40,624 | 37,715 | 34,563 | 33,683 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.